1349723-93-8
- Product Name：Elacestrant dihydrochloride
- Molecular Formula：C30H40Cl2N2O2
- Purity：99%
- Molecular Weight：531.6
Product Details:
CasNo： 1349723-93-8
Molecular Formula： C30H40Cl2N2O2
Chinese Manufacturer Supply Elacestrant dihydrochloride ,Wholesale 1349723-93-8 In Stock
- Molecular Formula:C30H40Cl2N2O2
- Molecular Weight:531.6
Elacestrant dihydrochloride 1349723-93-8 Usage
|
Description |
Elacestrant dihydrochloride is the hydrochloride salt form of elacestrant, which is an orally available selective estrogen receptor degrader (SERD). As an antineoplastic agent, elacestrant dihydrochloride acts as an estrogen receptor antagonist, inhibiting the activity of estrogen receptors in cancer cells. |
|
Uses |
It is approved for the treatment of advanced or metastatic breast cancer that is estrogen receptor-positive (ER+), HER2-negative, and has a mutation in the ESR1 gene. Elacestrant dihydrochloride is indicated for use in postmenopausal women and adult men whose cancer has progressed despite prior treatment with at least one type of hormone therapy. It targets and degrades estrogen receptors, thereby inhibiting estrogen signaling and slowing down the growth and spread of breast cancer cells. |
1349723-93-8 Relevant articles
ELACESTRANT IN COMBINATION WITH ABEMACICLIB IN WOMEN WITH BREAST CANCER
NK Aragam，M Charles
, EP3886826A1
The present disclosure relates to methods of treating breast cancer in a patient, comprising administering to the patient a therapeutic combination comprising elacestrant, or a pharmaceutically acceptable salt thereof, and abemaciclib, or a pharmaceutically acceptable salt thereof.
CRYSTAL FORM OF ELACESTRANT DIHYDROCHLORIDE, PREPARATION METHOD THEREFOR, AND USE THEREOF
-
WO2023/227029A1;WO2023000227029A1;WO2023227029A1;WO2023227029
The present invention relates to a novel crystal form of elacestrant (hereinafter referred to as "compound I") dihydrochloride, a preparation method therefor, a pharmaceutical composition containing the crystal form, and uses of the crystal form in the preparation of an estrogen receptor degrader drug and a drug for treating estrogen receptor-positive breast cancer, human epidermal growth factor receptor 2-negative breast cancer, or ESR1-mutated breast cancer.
Relevant Products
-
MilvexianCAS：1802425-99-5
-
AcalabrutinibCAS：1420477-60-6
-
2-NitrodiphenylamineCAS：119-75-5
